Topical cocaine can treat ABMD

Article

Cocaine-assisted epithelial debridement is a simple and inexpensive treatment method for symptomatic anterior basement membrane dystrophy (ABMD) patients, reveals the latest study in the journal Cornea.

Cocaine-assisted epithelial debridement is a simple and inexpensive treatment method for symptomatic anterior basement membrane dystrophy (ABMD) patients, reveals the latest study in the journal Cornea.

Dr Rony R. Sayegh et al., Department of Ophthalmology and Visual Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA, conducted a retrospective chart review on 33 eyes of 27 symptomatic patients with ABMD who were treated with 4% topical cocaine followed by epithelial debridement.

The main outcome measures included preoperative and postoperative best-corrected visual acuities (BCVA), topography, subjective symptoms, complications and evidence of disease recurrence.

Recurrent erosion symptoms were present in 17 eyes of 14 patients (group 1) and 16 eyes of 13 patients (group 2) experienced reduced visual acuity from irregular astigmatism.

Group 1 presented with one patient who experienced symptomatic recurrence of the corneal erosion. In group 2 one patient experienced significant postoperative corneal haze. BCVA in group 1 improved from an average of 20/45 preoperatively to 20/38 at the last follow-up visit and 20/63 to 20/32 in group 2.

The treatment is ideal for ABMD patients who experience recurrent corneal erosions or irregular astigmatism, causing decreased visual acuity.

Please click here to read the study abstract.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.